Skip to main content
SpringerLink
Log in

Erkrankungen der unteren Atemwege

  • Chapter
Klinische Pneumologie

  • 4477 Accesses

Auszug

Asthma hat viele Gesichter. Hierzu zählt zunächst die Häufigkeit der Erkrankung, die Asthma im wahrsten Sinne des Wortes zu einer »Volkskrankheit« macht. Hierher gehört die Einschränkung der Lebensqualität ebenso wie die Beeinträchtigung des sozialen Umfelds. Asthma bedingt aber auch Behinderungen im Berufsleben, sei es in Form einer verminderten körperlichen Leistungsfähigkeit oder einer Arbeitsunfähigkeit. Hierzu gehören ferner Kinder und Jugendliche, die durch Asthma in ihrer körperlichen und sozialen Entwicklung gestört werden können. Depressive Verstimmungen durch die chronische Krankheit oder Angstzustände vor Dyspnoeanfällen, die im Einzelfall die ganze Persönlichkeit des Asthmatikers bestimmen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Agertoft L, Pedersen S (2000) Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 343:1064–1069

    PubMed  CAS  Google Scholar 

  • Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ (2003) Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 112(3 Suppl):S1–40

    PubMed  CAS  Google Scholar 

  • Baur X, Barbinova L (2007) Messung von exhaliertem Stickstoffmonoxid: Klinischer Einsatz bei Atemwegserkrankungen. Deut Ärztebl 104:C669–675

    Google Scholar 

  • Bergmann N, Foerster M, Reißig A, Mock B, Workalemahu G, Kroegel C (2003) Immunomodulatory treatment of severe persisteant asthma with interferon-alfacon-1 (IFN-alfacon-1). Effect on the clinical course, oral corticosteroid dose and eosinophil numbers. Eur Respir J 22(Suppl.45): 379s

    Google Scholar 

  • Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P, and the Canadian Asthma Consensus Group (1999) The asthma consensus report 1999. CMAJ 161(11 Suppl.)S1–S6

    PubMed  CAS  Google Scholar 

  • British Thoracic Society, Scottish Intercollegiate Guidelines Network (2003) British guideline on the management of asthma. Thorax 58(Suppl 1):i1–i94

    Google Scholar 

  • Buhl R, Berdel D, Criée CP et al. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma bronchiale 2005. Pneumologie 60:139–179

    PubMed  CAS  Google Scholar 

  • Carbonari M, Tedesco T, Del Porto P, Paganelli R, Fiorilli M (2000) Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: consequences for immunopathogenesis. Clin Exp Immunol 120:454–462

    PubMed  CAS  Google Scholar 

  • Childhood Asthma Management Program Research Group (2000) Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054–1063

    Google Scholar 

  • Donohue JF, Ohar JA (2001) New combination therapies for asthma. Curr Opin Pulm Med 7:62–68

    PubMed  CAS  Google Scholar 

  • Gillissen A, Bergmann KC, Kleine-Tebbe J et al. (2003) Die Bedeutung der spezifischen Immuntherapie bei allergischem Asthma bronchiale. Dtsch Med Wschr 128:204–209

    PubMed  CAS  Google Scholar 

  • Global Initiative for Asthma (GINA) (2006) GINA workshop report, global strategy for asthma management and prevention. www.ginastma.org (last access Dec 22th 206)

    Google Scholar 

  • ISAAC Steering Committee (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjuctivitis, and atopic eczema: ISAAC. Lancet 351:1225–1232

    Google Scholar 

  • Kenn K (2007) Vocal Cord Dysfunction (VCD) — was wissen wir heute? Pneumologie 61:431–439

    PubMed  CAS  Google Scholar 

  • Kleine-Tebbe J, Fuchs T, Klimek L et al. (2000) Die spezifische Immuntherapie (Hyposensibilisierung mit Allergenen). Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J 9:317–324

    Google Scholar 

  • Kleine-Tebbe J, Kleine-Tebbe V, Kroegel C (2003) Grundlagen und Therapie des Asthma bronchiale. In: Merk HF, Schmutzler W (Hrsg.) Antiallergika und antiallergische Therapie, Schriftenreihe Medizinisch-pharmakologisches Kompendium, 1. Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 124–175

    Google Scholar 

  • Konietzko N, Fabel H (Hrsg.) Weißbuch Lunge 2005. Thieme, Stuttgart

    Google Scholar 

  • Kroegel C (2002) Asthma bronchiale — Pathogenetische Grundlagen, Diagnostik und Therapie, 2. überarb. u. erw. Aufl. Thieme, Stuttgart

    Google Scholar 

  • Kroegel C, Buhl R, Gillissen A, Petro W (2005) Asthma bronchiale versus chronisch-obstruktive Lungenkrankheit (COPD): Von der Pathogenese zur Differentialdiagnostik und Differentialtherapie. Dtsch Med Wschr 130:812–818

    PubMed  CAS  Google Scholar 

  • Kroegel C (2005) Asthmatherapie. Leitfaden einer pathogenetisch begründeten Behandlung, 2. vollst. überarb. u. ergänzte Aufl. Zett, Steinen

    Google Scholar 

  • Kroegel C (2007) Krankheitskontrolle als Therapieprinzip beim Asthma bronchiale. Global Initiative for Asthma Management and Prevention — GINA 2006. Pneumologie 61; 101–110

    Google Scholar 

  • Nowak D, von Mutius E (2004) Asthma bronchiale im Kindes-und Erwachsenenalter: Risikofaktoren, Diagnose, Standardtherapie. Dtsch med Wochenschr 129: 509–516

    PubMed  CAS  Google Scholar 

  • Selroos O, Pietinalho A, Löfroos AB, Riska H (1995) Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 108:1228–1234

    PubMed  CAS  Google Scholar 

  • Shorr AF, Torrington KG, Hnatiuk OW (2001) Endobronchial involvement and airway hyperreactivity in patients with sacoidosis. Chest 120:881–886

    PubMed  CAS  Google Scholar 

  • Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B (2000) Low-dose inhalated corticosteroids and the prevention of death from asthma. N Engl J Med 343:332–336

    PubMed  CAS  Google Scholar 

  • Thole H, Kroegel C, Bassler D et al. (2004) Das Leitlinien-Clearingverfahren Asthma bronchiale. Zusammenfassung und Empfehlungen zu Eckpunkten für eine nationale Leitlinie Asthma bronchiale. Pneumologie 58:165–175. (auch unter: http://www.leitlinien.de/clearingverfahren/clearingberichte/asthma/00asthma/view)

    PubMed  CAS  Google Scholar 

  • Van den Toorn LM (2004) Clinical implications of airway inflammation in mild intermittent asthma. Ann Allergy Asthma Immunol 92:589–594

    PubMed  Google Scholar 

Literatur

  • American Thoracic Society (1999) Pulmonary rehabilitation. Am J Respir Crit Care Med 159:1666–1682

    Google Scholar 

  • ATS/ ERS (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23(6):932–46

    Google Scholar 

  • Barnes PJ (2000) Chronic obstructive pulmonary disease. New Engl J Med 343:269–280

    PubMed  CAS  Google Scholar 

  • Bundeszentrale für gesundheitliche Aufklärung (2002) Jugendliche Raucher — Veränderungen des Rauchverhaltens und Ansätze für die Prävention. BZgA, Köln

    Google Scholar 

  • European Respiratory Society (ERS) und European Lung Foundation (ELF) (Hrsg ) European White Book Lung. ERS, Brüssel; Bestelladresse über www.ersnet.org/1/6/1_6asp

    Google Scholar 

  • Fletcher C, Peto R, Tinker R, Speitzer FE (1976) The Natural History of Chronic Bronchitis and Emphysema. Oxford University Press, Oxford

    Google Scholar 

  • Gatt ME, Heyman SN (2002) Treatment of tobacco use and dependance. New Engl J Med 347:294–295

    PubMed  Google Scholar 

  • GOLD (2006) Global Strategy for Diagnosis, Management, and Prevention of COPD — Evidence based guidelines for COPD diagnosis, management, and prevention. http://www.goldcopd.org

    Google Scholar 

  • Höffken G et al. (2005) Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exazerbation einer chronischen Bronchitis, Influenza und andere respiratorische Virusinfektionen) sowie ambulant erworbene Pneumonie — S3 Leitlinien der Paul Ehrlich Gesellschaft. Chemotherapie J 14(4):S97–155

    Google Scholar 

  • Konietzko N, Fabel H (Hrsg) (2000) Weißbuch Lunge 2000. Thieme, Stuttgart

    Google Scholar 

  • Lundbäck B, Lindberg A, Lindström M et al. (2003) Not 15 but 20% of Smokers Develop COPD? — Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 97:115–122

    PubMed  Google Scholar 

  • Magnussen H, Goeckenjan G, Köhler D, Matthys H, Morr H, Worth H, Wuthe H (2001) Leitlinien zur Sauerstofflangzeittherapie. Pneumologie 55: 454–464

    PubMed  CAS  Google Scholar 

  • NICE (2004) NICE guideline to improve care of patient with chronic obstructive pulmonary disease und CG12 Chronic obstructive pulmonary disease. www.nice.org.uk/cat.asp?c=104441

    Google Scholar 

  • Vogelmeier C, Buhl R, Criée CP et al (2007) Leitlinien der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch-obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 61(5):el–e40

    Google Scholar 

Literatur

  1. Anderson MP, Welsh MJ (1992) Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 257:1701–1704

    PubMed  CAS  Google Scholar 

  2. Aris RM, Lester GE, Caminiti M et al. (2004) Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 169:77–82

    PubMed  Google Scholar 

  3. Aris RM, Renner JB, Winders AD et al. (1998) Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 128:186–193

    PubMed  CAS  Google Scholar 

  4. Ballmann M, Smaczny C (1998) CF-Manual. Solvay Arzneimittel, Hannover

    Google Scholar 

  5. Ballmann M, Rabsch P, von der Hardt H (1998) Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 53:732–737

    PubMed  CAS  Google Scholar 

  6. Bargon J, Stein J, Dietrich CF et al. (1999) Gastrointestinale Probleme erwachsener Patienten mit Cystischer Fibrose. Z Gastroenterol 37:739–749

    PubMed  CAS  Google Scholar 

  7. Barker M, Hebestreit A, Gruber W et al. (2004) Exercise testing and training in German CF centers. Pediatr Pulmonol 37:351–355

    PubMed  Google Scholar 

  8. Bradley JM, Moran FM, Elborn JS (2006) Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med 100:191–201

    PubMed  Google Scholar 

  9. Brody AS, Tiddens HA, Castile RG et al. (2005) Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 172:1246–1252

    PubMed  Google Scholar 

  10. Bundesministerium für Gesundheit (2006) Bekanntmachung des Gemeinsamen Bundesausschusses vom 13.11.2006: Richtlinie zur Diagnostik und Versorgung von Patienten mit Mukoviszidose. B Anz 213:6927

    Google Scholar 

  11. Chmiel JF, Berger M, Konstan MW (2002) The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 23:5–27

    PubMed  Google Scholar 

  12. Cohen RG, Starnes VA (2001) Living donor lung transplantation. World J Surg 25:244–250

    PubMed  CAS  Google Scholar 

  13. Colombo C, Battezzati PM, Strazzabosco M et al. (1998) Liver and biliary problems in cystic fibrosis. Semin Liver Dis 18:227–235

    PubMed  CAS  Google Scholar 

  14. Conway SP, Pond MN, Bowler I et al. (1994) The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 49:860–862

    PubMed  CAS  Google Scholar 

  15. Doring G, Conway SP, Heijerman HG et al. (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16:749–767

    PubMed  CAS  Google Scholar 

  16. Drumm ML, Konstan MW, Schluchter MD et al. (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443–1453

    PubMed  CAS  Google Scholar 

  17. Duijvestijn YC, Brand PL (1999) Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 88:38–41

    PubMed  CAS  Google Scholar 

  18. Elkins MR, Robinson M, Rose BR et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354:229–240

    PubMed  CAS  Google Scholar 

  19. Elphick H, Southern K (2000) Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev CD002204

    Google Scholar 

  20. Emerson J, Rosenfeld M, McNamara S et al. (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91–100

    PubMed  Google Scholar 

  21. Estenne M, Kotloff RM (2006) Update in transplantation 2005. Am J Respir Crit Care Med 173:593–598

    PubMed  Google Scholar 

  22. Farrell PM, Kosorok MR, Laxova A et al. (1997) Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 337:963–969

    PubMed  CAS  Google Scholar 

  23. Farrell PM, Lai HJ, Li Z et al. (2005) Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 147:S30–S36

    PubMed  Google Scholar 

  24. Ferrari S, Griesenbach U, Geddes DM et al. (2003) Immunological hurdles to lung gene therapy. Clin Exp Immunol 132:1–8

    PubMed  CAS  Google Scholar 

  25. Fuchs HJ, Borowitz DS, Christiansen DH et al. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331:637–642

    PubMed  CAS  Google Scholar 

  26. Gibson RL, Emerson J, McNamara S et al. (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167:841–849

    PubMed  Google Scholar 

  27. Goetz M (2001) Fertilität bei CF Patienten. In: Reinhardt D, Goetz M, Kraemer RH, Schoeni MH (Hrsg). Cystische Fibrose. Springer, Berlin

    Google Scholar 

  28. Grey AB, Ames RW, Matthews RD et al. (1993) Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 48:589–593

    PubMed  CAS  Google Scholar 

  29. Grove JE, Lutzko C, Priller J et al. (2002) Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol 27:645–651

    PubMed  CAS  Google Scholar 

  30. Gysin C, Alothman GA, Papsin BC (2000) Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol 30:481–489

    PubMed  CAS  Google Scholar 

  31. Haardt M, Benharouga M, Lechardeur D et al. (1999) C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 274:21873–21877

    PubMed  CAS  Google Scholar 

  32. Hardin DS, Adams-Huet B, Brown D et al. (2006) Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 91:4925–4929

    PubMed  CAS  Google Scholar 

  33. Hirche TO, Atkinson JJ, Bahr S et al. (2004) Deficiency in neutrophil elastase does not impair neutrophil recruitment to inflamed sites. Am J Respir Cell Mol Biol 30:576–584

    PubMed  CAS  Google Scholar 

  34. Hirche TO, Loitsch S, Smaczny C et al. (2006) Zystische Fibrose. Pneumologe 3:325–339

    Google Scholar 

  35. Hirche TO, Loitsch S, Smaczny C et al. (2005) Neue Konzepte zur Pathophysiologie und Therapie der Mukoviszidose. Pneumologie 59:811–818

    PubMed  CAS  Google Scholar 

  36. Hirche TO, Smaczny C, von Mallinckrodt C et al. (2003) Pulmonale Manifestation der Mukoviszidose im Erwachsenenalter. Dtsch Arztebl 100:264–270

    Google Scholar 

  37. Hodson ME, Gallagher CG, Govan JR (2002) A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20:658–664

    PubMed  CAS  Google Scholar 

  38. Imundo L, Barasch J, Prince A et al. (1995) Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 92:3019–3023

    PubMed  CAS  Google Scholar 

  39. Johnson LG, Boyles SE, Wilson J et al. (1995) Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 95:1377–1382

    PubMed  CAS  Google Scholar 

  40. Kelley TJ, Thomas K, Milgram LJ et al. (1997) In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci USA 94:2604–2608

    PubMed  CAS  Google Scholar 

  41. Kerem E, Conway S, Elborn S et al. (2005) Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4:7–26

    PubMed  Google Scholar 

  42. Kerem E, Corey M, Kerem BS et al. (1990) The relation between genotype and phenotype in cystic fibrosis—analysis of the most common mutation (delta F508). N Engl J Med 323:1517–1522

    PubMed  CAS  Google Scholar 

  43. Kerrebijn JD, Poublon RM, Overbeek SE (1992) Nasal and paranasal disease in adult cystic fibrosis patients. Eur Respir J 5:1239–1242

    PubMed  CAS  Google Scholar 

  44. Keswani SG, Crombleholme TM (2004) Gene transfer to the tracheobronchial tree: implications for fetal gene therapy for cystic fibrosis. Semin Pediatr Surg 13:44–52

    PubMed  Google Scholar 

  45. Knauer N, Ratjen F, Grasemann H (2005) Modifizierende Gene bei der zystischen Fibrose. Pneumologie 59:395–404

    PubMed  CAS  Google Scholar 

  46. Knowles MR, Boucher RC (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109:571–577

    PubMed  CAS  Google Scholar 

  47. Lindemann H, Wunderlich P (1997) Atemwege und Lunge. In: Dockter G, Lindemann H, Tuemmler B, Wunderlich P, Dittrich-Weber H (Hrsg). Mukoviszidose, 2. Aufl. Thieme, Stuttgart

    Google Scholar 

  48. Liou TG, Adler FR, Cahill BC et al. (2001) Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 286:2683–2689

    PubMed  CAS  Google Scholar 

  49. Massie RJ, Towns SJ, Bernard E et al. (1998) The musculoskeletal complications of cystic fibrosis. J Paediatr Child Health 34:467–470

    PubMed  CAS  Google Scholar 

  50. Matsui H, Grubb BR, Tarran R et al. (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005–1015

    PubMed  CAS  Google Scholar 

  51. Milla CE, Warwick WJ (1998) Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 113:1230–1234

    PubMed  CAS  Google Scholar 

  52. Nilius B, Droogmans G (2003) Amazing chloride channels: an overview. Acta Physiol Scand 177:119–147

    PubMed  CAS  Google Scholar 

  53. Onady GM, Stolfi A (2005) Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev CD004730

    Google Scholar 

  54. Paul K, Rietschel E, Ballmann M et al. (2004) Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 169:719–725

    PubMed  Google Scholar 

  55. Pier GB, Grout M, Zaidi TS et al. (1996) Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271:64–67

    PubMed  CAS  Google Scholar 

  56. Powell K, Zeitlin PL (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev 54:1395–1408

    PubMed  CAS  Google Scholar 

  57. Quinton PM (1990) Cystic fibrosis: a disease in electrolyte transport. FASEB J 4:2709–2717

    PubMed  CAS  Google Scholar 

  58. Ramsey BW, Pepe MS, Quan JM et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23–30

    PubMed  CAS  Google Scholar 

  59. Ratjen F (2006) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 12:428–432

    PubMed  CAS  Google Scholar 

  60. Ratjen F, Paul K, van Koningsbruggen S et al. (2005) DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 39:1–4

    PubMed  CAS  Google Scholar 

  61. Riordan JR, Rommens JM, Kerem B et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073

    PubMed  CAS  Google Scholar 

  62. Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589–595

    PubMed  CAS  Google Scholar 

  63. Saiman L, Marshall BC, Mayer-Hamblett N et al. (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749–1756

    PubMed  CAS  Google Scholar 

  64. Salamoni F, Roulet M, Gudinchet F et al. (1996) Bone mineral content in cystic fibrosis patients: correlation with fat-free mass. Arch Dis Child 74:314–318

    PubMed  CAS  Google Scholar 

  65. Selvadurai HC, Blimkie CJ, Meyers N et al. (2002) Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis. Pediatr Pulmonol 33:194–200

    PubMed  CAS  Google Scholar 

  66. Sheppard DN, Rich DP, Ostedgaard LS et al. (1993) Mutations in CFTR associated with mild-disease-form Cl-channels with altered pore properties. Nature 362:160–164

    PubMed  CAS  Google Scholar 

  67. Sinaasappel M, Stern M, Littlewood J et al. (2002) Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 1:51–75

    PubMed  CAS  Google Scholar 

  68. Singh PK, Schaefer AL, Parsek MR et al. (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762–764

    PubMed  CAS  Google Scholar 

  69. Smith JJ, Travis SM, Greenberg EP et al. (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229–236

    PubMed  CAS  Google Scholar 

  70. Smyth A, Walters S (2003) Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev CD001912

    Google Scholar 

  71. Sokol RJ, Durie PR (1999) Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 28:1–13

    Google Scholar 

  72. Stein J, Jung M, Sziegoleit A et al. (1996) Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem 42:222–226

    PubMed  CAS  Google Scholar 

  73. Steinkamp G, Wiedemann B (2002) Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57:596–601

    PubMed  CAS  Google Scholar 

  74. Stern M, Sens B, Wiedemann B et al. (2006) Qualitätsicherung Mukoviszidose — Überblick über den Gesundheitszustand der Patienten in Deutschland 2005. Zentrum für Qualitätsmanagement im Gesundheitswesen Hannover, www.muko.info

    Google Scholar 

  75. Stevens DA, Moss RB, Kurup VP et al. (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis — state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37:S225–S264

    PubMed  Google Scholar 

  76. Stover CK, Pham XQ, Erwin AL et al. (2000) Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406:959–964

    PubMed  CAS  Google Scholar 

  77. Taccetti G, Campana S, Festini F et al. (2005) Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26:458–461

    PubMed  CAS  Google Scholar 

  78. Taylor CJ, Aswani N (2002) The pancreas in cystic fibrosis. Paediatr Respir Rev 3:77–81

    PubMed  CAS  Google Scholar 

  79. Trout L, King M, Feng W et al. (1998) Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. Am J Physiol 274:L258–L263

    PubMed  CAS  Google Scholar 

  80. Tsui LC, Durie P (1997) Genotype and phenotype in cystic fibrosis. Hosp Pract 32:115–134

    CAS  Google Scholar 

  81. von Mallinckrodt C, Smaczny C, Hirche TO et al. (2005) Lungentransplantation bei Mukoviszidose. Atemw-Lungenkrkh 31:64–70

    Google Scholar 

  82. Wagner T.O. (2005) Mukoviszidose. 3: In: Schoelmerich J (Hrsg.). Medizinische Therapie in Klinik und Praxis. Springer, Berlin

    Google Scholar 

  83. Wagner T, Soong G, Sokol S et al. (2005) Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128:912–919

    PubMed  CAS  Google Scholar 

  84. Ward CL, Kopito RR (1994) Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 269:25710–25718

    PubMed  CAS  Google Scholar 

  85. Wiedemann B, Paul K, Stern M et al. (2007) Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. Eur J Clin Nutr in press

    Google Scholar 

  86. Wood DM, Smyth AR (2006) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev CD004197

    Google Scholar 

  87. Worlitzsch D, Tarran R, Ulrich M et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317–325

    PubMed  CAS  Google Scholar 

  88. Yalcin E, Kiper N, Dogru D et al. (2005) Clinical features and treatment approaches in cystic fibrosis with pseudo-Bartter syndrome. Ann Trop Paediatr 25:119–124

    PubMed  Google Scholar 

  89. Zabner J, Couture LA, Gregory RJ et al. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207–216

    PubMed  CAS  Google Scholar 

  90. Zabner J, Smith JJ, Karp PH et al. (1998) Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell 2:397–403

    PubMed  CAS  Google Scholar 

  91. Zar H, Saiman L, Quittell L et al. (1995) Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 126:230–233

    PubMed  CAS  Google Scholar 

  92. Zielenski J (2000) Genotype and phenotype in cystic fibrosis. Respiration 67:117–133

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I Schwerpunkt Pneumologie/Allergologie, Klinikum der Johann-Wolfgang-Goethe Universität, Theodor-Stern-Kai 7, 60590, Frankfurt

    Dr. med. T. O. Hirche & Prof. Dr. med. T. O. F. Wagner

  2. Klinik für Innere Medizin I Fachbereich Pneumologie, Klinikum der Universität Jena, Erlanger Allee 101, 07740, Jena

    Prof. Dr. med. C. Kroegel

  3. Innere Medizin, SP Pneumologie, Universitätsklinik der Philipps-Universität, Baldinger Str., 35043, Marburg

    Dr. med. A. Rembert Koczulla & Prof. Dr. med. C. Vogelmeier

  4. Hochrüttestraße 17, 79117, Freiburg

    Prof. Dr. med. H. Matthys

Authors
  1. Dr. med. T. O. Hirche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. C. Kroegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. A. Rembert Koczulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. H. Matthys
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. C. Vogelmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. med. T. O. F. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hochrüttestraße 17, 79117, Freiburg i. Br.

    Heinrich Matthys

  2. Medizinische Klinik II, Justus-Liebig-Universität Gießen, Klinikstraße 36, 35392, Gießen

    W. Seeger

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hirche, T.O., Kroegel, C., Rembert Koczulla, A., Matthys, H., Vogelmeier, C., Wagner, T.O.F. (2008). Erkrankungen der unteren Atemwege. In: Matthys, H., Seeger, W. (eds) Klinische Pneumologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37692-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-37692-7_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-37682-8

  • Online ISBN: 978-3-540-37692-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation